Bennett Ryan C, Keen Justin M, Bi Yunxia Vivian, Porter Stuart, Dürig Thomas, McGinity James W
Division of Pharmaceutics, The University of Texas at Austin, Austin, TX, USA.
Pharmaceutical and Nutritional Technology, R&D, Ashland Specialty Ingredients, Wilmington, DE, USA.
J Pharm Pharmacol. 2015 Jul;67(7):918-38. doi: 10.1111/jphp.12388. Epub 2015 Feb 3.
This study focuses on the application of hot melt extrusion (HME) to produce solid dispersions containing griseofulvin (GF) and investigates the in-vitro dissolution performance of HME powders and resulting tablet compositions containing HME-processed dispersions.
Binary, ternary and quaternary dispersions containing GF, enteric polymer (Eudragit L100-55 or AQOAT-LF) and/or vinyl pyrrolidone-based polymer (Plasdone K-12 povidone or S-630 copovidone) were processed by HME. Two plasticizers, triethyl citrate (TEC) and acetyl tributyl citrate (ATBC), were incorporated to aid in melt processing and to modify release of GF in neutral media following a pH-change in dissolution. Products were characterized for GF recovery, degrees of compositional amorphous character, intermolecular interactions and non-sink dissolution performance.
Binary dispersions exhibited lower maximum observed concentration values and magnitudes of supersaturated GF in neutral media dissolution in comparison with the ternary dispersions. The quaternary HME products, 1 : 2 : 1 : 0.6 GF : L100-55 : S-630 : ATBC and GF : AQOAT-LF : K-12 : ATBC, were determined as the most optimal concentration-enhancing compositions due to increased hydrogen bonding of enteric functional groups with carbonyl/acetate groups of vinyl pyrrolidone-based polymers, reduced compositional crystallinity and presence of incorporated hydrophobic plasticizer.
HME products containing combinations of concentration-enhancing polymers can supersaturate and sustain GF dissolution to greater magnitudes in neutral media following the pH-transition and be compressed into immediate-release tablets exhibiting similar dissolution profiles.
本研究聚焦于应用热熔挤出(HME)技术制备含灰黄霉素(GF)的固体分散体,并研究HME粉末以及含有经HME处理的分散体的片剂组合物的体外溶出性能。
通过HME制备含GF、肠溶聚合物(尤特奇L100 - 55或醋酸羟丙甲纤维素琥珀酸酯-LF)和/或乙烯基吡咯烷酮基聚合物(聚维酮K-12或共聚维酮S-630)的二元、三元和四元分散体。加入两种增塑剂柠檬酸三乙酯(TEC)和乙酰柠檬酸三丁酯(ATBC)以辅助熔融加工,并在溶出过程中pH值变化后改变GF在中性介质中的释放。对产品进行GF回收率、组成非晶态特征程度、分子间相互作用和非漏槽溶出性能的表征。
与三元分散体相比,二元分散体在中性介质溶出中表现出较低的最大观察浓度值和过饱和GF的量。由于肠溶官能团与乙烯基吡咯烷酮基聚合物的羰基/醋酸酯基团之间氢键增加、组成结晶度降低以及加入了疏水性增塑剂,确定四元HME产品1∶2∶1∶0.6的GF∶L100 - 55∶S-630∶ATBC和GF∶醋酸羟丙甲纤维素琥珀酸酯-LF∶K-12∶ATBC为最优化的浓度增强组合物。
含有浓度增强聚合物组合的HME产品在pH转变后可在中性介质中超饱和并维持GF的更大程度溶出,并且可压制成具有相似溶出曲线的速释片剂。